Canntab Therapeutics Ltd
CNSX:PILL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Canntab Therapeutics Ltd
Accounts Receivables
Canntab Therapeutics Ltd
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Canntab Therapeutics Ltd
CNSX:PILL
|
Accounts Receivables
CA$26.3k
|
CAGR 3-Years
-52%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
High Tide Inc
XTSX:HITI
|
Accounts Receivables
CA$20.1m
|
CAGR 3-Years
25%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
Canopy Growth Corp
TSX:WEED
|
Accounts Receivables
CA$29m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
43%
|
|
|
OrganiGram Holdings Inc
TSX:OGI
|
Accounts Receivables
CA$49.1m
|
CAGR 3-Years
19%
|
CAGR 5-Years
33%
|
CAGR 10-Years
51%
|
|
|
Sundial Growers Inc
NASDAQ:SNDL
|
Accounts Receivables
CA$27.6m
|
CAGR 3-Years
7%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Accounts Receivables
$34.1m
|
CAGR 3-Years
14%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
Canntab Therapeutics Ltd
Glance View
Canntab Therapeutics Ltd. is a biopharmaceutical company. The company is headquartered in Toronto, Ontario. The company went IPO on 2011-04-21. The firm is focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. The firm operates in one reportable operating, being engaged in the medical marijuana business. All property and equipment, right-of-use assets and intangible assets are located in Canada. Its hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions. Its products include INSTANT RELEASE - (IR Tablet), EXTENDED-RELEASE - (XR Tablet), and ORAL DISSOLVING - O.D. Tablet. The company holds cannabis standard processing and sales for medical purposes license, a cannabis research license, and an industrial hemp license from health Canada.
See Also
What is Canntab Therapeutics Ltd's Accounts Receivables?
Accounts Receivables
26.3k
CAD
Based on the financial report for May 31, 2022, Canntab Therapeutics Ltd's Accounts Receivables amounts to 26.3k CAD.
What is Canntab Therapeutics Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 3Y
-52%
The average annual Accounts Receivables growth rates for Canntab Therapeutics Ltd have been -52% over the past three years .
